Exosome RNA Exosome RNA Research & Industry News
Aggressive cancers such as triple-negative breast cancer and pancreatic cancer can be especially difficult to treat because their behavior is controlled by complex networks of genes. Instead of depending on a single molecular pathway, cancer cells can use multiple mechanisms to support rapid growth, invasion, and survival. This complexity has encouraged researchers to investigate treatments capable of influencing several cancer-related pathways at the same time.
Researchers at the Research Saint-Louis Institute (IRSL), INSERM, France investigated whether extracellular vesicles could deliver a combination of regulatory RNA molecules capable of suppressing aggressive cancer behavior.
Extracellular vesicles, or EVs, are small membrane-bound particles released by cells. They transport proteins, lipids, RNA, and other molecules between cells, allowing them to influence the behavior of neighboring or distant cells. Because EVs naturally transport biological cargo, researchers are increasingly investigating whether they can also be engineered to deliver therapeutic molecules.
The researchers focused on microRNAs, or miRNAs, which are short RNA molecules that regulate gene expression. Rather than encoding proteins themselves, miRNAs can reduce the activity of specific genes. Importantly, individual miRNAs can influence multiple genes, making combinations of miRNAs potentially useful for targeting the complex networks that support aggressive cancers.
Previous research had linked the transcription factor NFAT3 with reduced tumor aggressiveness. The researchers found that extracellular vesicles associated with NFAT3 activity carried a distinctive group of miRNAs that appeared to contribute to these anti-tumor effects.
To determine which miRNAs were responsible, the team evaluated different combinations and identified a group of 15 miRNAs, called miR-Comb 15. The complete combination was required to reproduce the strongest anti-tumor effects of NFAT3-regulated extracellular vesicles across models of triple-negative breast cancer and pancreatic cancer.
Individual miRNAs produced only part of the effect. In contrast, the combination influenced multiple genes involved in cancer cell proliferation and invasion. This suggests that the miRNAs work together to interfere with a broader network of processes supporting aggressive tumor behavior.
The researchers then addressed an important challenge for developing an EV-based therapy, finding a practical source of extracellular vesicles that could be produced and engineered at scale. They selected HEK 293T cells, a widely used non-tumor cell line that can serve as a source of EVs.
Rather than genetically modifying the cells to produce all 15 miRNAs, the researchers loaded the miRNA combination directly into extracellular vesicles after the vesicles had been produced. They used a pH-gradient loading technique that efficiently incorporated miR-Comb 15 without disrupting EV structure or their inherent biological properties.
When the engineered extracellular vesicles were tested in cell and animal models, HEK 293T-derived EVs carrying miR-Comb 15 produced the strongest anti-tumor activity among the delivery systems evaluated. The treatment reduced cancer-associated proliferation and invasion, supporting the idea that EVs can function as carriers for complex combinations of therapeutic RNA molecules.
The findings are particularly interesting because they illustrate a different approach to RNA-based cancer therapy. Instead of delivering one RNA molecule designed to affect one target, extracellular vesicles could potentially carry carefully selected combinations of miRNAs that regulate multiple parts of a cancer-associated gene network simultaneously.
Significant work remains before such an approach could be considered for clinical treatment. Researchers will need to establish safe and reproducible manufacturing methods, determine appropriate doses, evaluate how engineered EVs distribute throughout the body, and establish whether their miRNA cargo can be delivered selectively to tumors without producing unwanted effects in healthy tissues.
Still, the results demonstrate how extracellular vesicles could provide a biological delivery system for combinatorial RNA therapeutics. By combining the natural cargo-carrying properties of EVs with carefully selected miRNA combinations, researchers may be able to develop new strategies for targeting cancers whose complexity makes them difficult to control with single-target therapies.
